Navigation Links
GenScript Announces Joint Road Show with Open Monoclonal Technology, Inc.
Date:1/22/2013

PISCATAWAY, N.J., Jan. 22, 2013 /PRNewswire/ -- GenScript and Open Monoclonal Technology, Inc. (OMT) today announced a joint road show with potential clients across the US, China, Japan and South Korea in late January and early February. The road show will offer prospective clients introductions to GenScript and OMT's human antibody discovery technologies and explore new ways of accelerated and improved development of this important class of human therapeutics.

GenScript

GenScript offers a full spectrum of human antibody services, including target screening and expression, immunization, monoclonal antibody screening at any desired high complexity, antibody sequencing and characterization, biological and other assays, antibody production cell line development, model animal-based efficacy studies and more. GenScript's antibody development team consists of senior scientists and business managers who have extensive experience in therapeutic antibody development. They have been involved in the full process of therapeutic drug development. GenScript has already successfully gained a top position in gene synthesis worldwide, and has established leading positions in many other biology service areas.

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the development of human therapeutic antibodies – naturally optimized human antibodies™. OMT has created OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat™ uses an improved understanding of B cell development and a new approach to inactivation of endogenous antibody expression, which enables them to make antibodies with human idiotypes as efficiently as wild type rats make normal antibodies. OmniRat™ represents a novel and proprietary technology with unrestricted development options for fully human monoclonal antibodies, available worldwide for all targets and indications. OMT also develops a transgenic mouse, OmniMouse™, to complement OmniRat™ and further increase epitope coverage in human antibody development. OmniAb™ integrates OMT's transgenic animal platforms, proven protein- and DNA-mediated immunization and Gel-Encapsulated Microenvironment (GEM) deep antibody screening to enable fast and cost-efficient generation and identification of preferred human therapeutic antibody candidates.

Web site: www.genscript.com

 


'/>"/>
SOURCE GenScript USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenScript anuncia un programa conjunto con Open Monoclonal Technology, Inc.
2. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
3. GenScript anuncia una muestra itinerante conjunta con Open Monoclonal Technology, Inc.
4. GenScript Anuncia Exposição Itinerante Junto com a Open Monoclonal Technology, Inc.
5. TNI BioTech, Inc. Announces Appointment of New CFO
6. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
7. BioDelivery Sciences Announces Completion of BNX Safety Study
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
10. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
11. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading ... by Accera, Inc. at 11 a.m. EST ... International Conference on Clinical Trials for Alzheimer,s Disease (CTAD). ... metabolism in Alzheimer,s disease and therapeutic targets that address ... "Following the recent failure of another therapy targeting ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, ... Companies) - Global Forecasts to 2021" report to their offering. ... , , ... reach USD 730.7 Million in 2021 from USD 574.8 Million in ...
(Date:12/5/2016)... and PUNE, India , December 5, 2016 /PRNewswire/ ... titled, "Surgical Sutures Market by Product Type and by Application - Global Opportunity ... for $3,360 million in 2015, and is expected to reach $5,255 million by ... segment dominated the market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 2016 , ... Just in time for the holiday season, the celebrated paleo ... for Honeyville’s new Organic Quinoa Flour product for sale at Costco stores throughout the ... , “I think it’s wonderful that a growing number of retailers such as ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement ... of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of a powerful woman's story of sacrifice and enlightenment. , “Tatiana ... author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing through ...
(Date:12/6/2016)... ... December 06, 2016 , ... The OSHA Training Center ... Education Center headquartered in Northern California, has announced the addition of a Public ... health training to public sector employees. , “The primary goal of the Public ...
(Date:12/5/2016)... ... 05, 2016 , ... What: Shriners Hospitals for Children, with the help of ... – using a video monitor and web-enabled camera. Santa visits with children through Dimension ... a Christmas Wonderland, which is where the video connection to the North Pole will ...
Breaking Medicine News(10 mins):